Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 19/20 | 0.61 |
| ▸ | KDM6B | O15054 | 8/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | KDM4A | O75164 | 2/20 | 0.60 |
| ▸ | KDM4D | Q6B0I6 | 2/20 | 0.60 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.55 |
| ▸ | KDM5C | P41229 | 1/20 | 0.53 |
| ▸ | KDM5A | P29375 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9592036 | 0.80 | TP53 (0.47) | KDM4CKDM6BKDM4EKDM4AKDM4D | |
| SCHEMBL17378750 | 0.80 | KDM4C (0.65) | KDM4CKDM6BKDM4EKDM4AKDM4D | |
| SCHEMBL10719056 | 0.79 | KDM4C (0.77) | KDM4CKDM6BKDM4EKDM4AKDM4D | |
| SCHEMBL29915668 | 0.77 | ALDH1A1 (0.57) | KDM4E | |
| SCHEMBL587283 | 0.77 | ALDH1A1 (0.57) | KDM4E | |
| SCHEMBL1714819 | 0.76 | KDM4C (0.85) | KDM4CKDM6BKDM4EKDM4AKDM4D | |
| SCHEMBL15295165 | 0.76 | KDM4C (1.00) | KDM4CKDM6BKDM4EKDM4AKDM4D | |
| SCHEMBL20982055 | 0.74 | KDM4C (0.70) | KDM4CKDM6BKDM4EKDM4AKDM4D | |
| SCHEMBL15286471 | 0.74 | KDM4C (1.00) | KDM4CKDM6BKDM4EKDM4AKDM4D | |
| SCHEMBL17378640 | 0.74 | KDM4C (1.00) | KDM4CKDM6BKDM4EKDM4AKDM4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013143597-A1 | DEMETHYLASE ENZYMES INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-10-03 | — | — | WO | disclosed |
| EP-1996553-A2 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | Avanir Pharmaceuticals (US) | 2008-12-03 | — | — | EP | disclosed |
| US-20080139551-A1 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | AVANIR PHARMACEUTICALS (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2007109251-A2 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | AVANIR PHARMACEUTICALS (US) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139551-A1 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | TNF, TNFRSF1A, TNFRSF9 | KDM4C 4815/4885KDM6B 4808/4885KDM4E 4691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.